Diabetes Type 2 Clinical Trial
Official title:
Efficacy of a Specific Physiotherapy Group Treatment on Gait and Balance in Patients With Diabetic Neuropathy
Type 2 diabetes is one of the fastest growing public health problems in both developed and
developing countries. It is estimated that the number of people with diabetes in the world
will double in coming years, from 171 million in 2000 to 366 million in 2030.The role of
physiotherapy in diabetic care is to reduce immobilisation effects, to maintain functional
capacity and to minimise diabetes-related complications. The physiotherapist also has a role
in providing advice about exercise and daily living activities. The fundamental principle of
rehabilitation is to improve quality of life while diminishing the health care burden. By
reducing the heightened risk of falling, the fall related injuries and the fear of falling
one could improve quality of life in diabetic patients and reduce health care costs.
The goal of this study is to investigate the effectiveness of gait and balance training in
pre frail subgroup diabetes patients. Our program is based on recommendations of Robertson
et al.(2002) and Page et al.(2002) The investigators randomly assign patients in a control
group (no treatment) or in a treatment group. The treatment program consists of two group
sessions per week over 12 weeks. Patients were encouraged to perform specific home
exercises. After this 12-week program, patients were asked to continue their exercises. The
effect of the treatment will be evaluated after the treatment program and after a 6-month
follow up.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Active, not recruiting |
NCT04954313 -
Baseline Oral Health Study: UnCoVer the Connections to General Health
|
Phase 4 | |
| Not yet recruiting |
NCT06437782 -
Exploration of Health Literacy in Diabetes in Reunion Island and France
|
||
| Completed |
NCT01354925 -
Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
|
Phase 4 | |
| Completed |
NCT01206725 -
Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
|
N/A | |
| Completed |
NCT00997282 -
A Study of OPC-262 in Patients With Type 2 Diabetes
|
Phase 2/Phase 3 | |
| Completed |
NCT00464880 -
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02057497 -
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
|
N/A | |
| Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
| Recruiting |
NCT03662217 -
Personalized Nutrition for Diabetes Type 2
|
N/A | |
| Completed |
NCT04276051 -
Cryovagotomy Diabetes Trial
|
N/A | |
| Completed |
NCT02569684 -
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
| Terminated |
NCT01722474 -
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
|
N/A | |
| Completed |
NCT00977262 -
Postprandial Inflammation and Fatty Acids
|
N/A | |
| Completed |
NCT00518427 -
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
Phase 4 | |
| Recruiting |
NCT05378620 -
Project Dulce for Filipino-Americans With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT03834207 -
A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
|
N/A | |
| Active, not recruiting |
NCT05228067 -
Enhancing Brain Health by tDCS in Persons With Overweight and Obesity
|
N/A | |
| Active, not recruiting |
NCT05689684 -
Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes
|
N/A |